Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
ENvue Medical, Inc. (Name of Issuer) |
Common Stock, par value $0.001 per share (Title of Class of Securities) |
63008J884 (CUSIP Number) |
Christian Glibert 4001 Green Heron Spring Drive, Carpinteria, CA, 93013 740-507-7228 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
01/14/2026 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 63008J884 |
| 1 |
Name of reporting person
Glibert Christian Michael | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
| ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
240,000.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
6.5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, par value $0.001 per share |
| (b) | Name of Issuer:
ENvue Medical, Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
969 PRUITT AVE,, 969 PRUITT AVE,, TYLER,
TEXAS
, 77569. |
| Item 4. | Purpose of Transaction |
This Amendment No. 1 to Schedule 13D is being filed to report a material change in the Reporting Person's percentage of beneficial ownership of the Issuer's Common Stock. Since the filing of the initial Schedule 13D on February 11, 2026, the Issuer's total shares outstanding increased from 1,088,192 to 3,700,908, as reported in the Issuer's Annual Report on Form 10-K filed on April 15, 2026. This increase in outstanding shares resulted in the dilution of the Reporting Person's beneficial ownership from approximately 22.1 percent to approximately 6.5 percent. The Reporting Person has not acquired or disposed of any shares of Common Stock since the initial filing. The Reporting Person continues to hold the shares for investment purposes and may, from time to time, purchase additional shares or dispose of existing shares in the open market or in private transactions, depending on market conditions and other factors. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | 240,000 shares which is 6.5% of shares |
| (b) | Sole power to vote: 240,000 Shared power to vote: 0 Sole power to dispose: 240,000 Shared power to dispose: 0 |
| (c) | none |
| (d) | not applicable |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
The information set forth in Item 6 of the initial Schedule 13D is incorporated herein by reference. There have been no material changes to the contracts or arrangements previously reported. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|